Levocabastine nasal spray
Generic name
Levocabastine nasal spray
Brand name
ATC Code
R01AC02
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In children and adolescents aged between 6 and 17 years who received levocabastine nasal spray for four weeks (in varying doses up to a maximum of 0.2 mg four times a day), the plasma concentrations of levocabastine were either undetectable or ranged up to a maximum of 18.2 ng/ml. No comparison can be made with adults based on the little information that is available.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Allergic rhinitis |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Sympathomimetics, plain | ||
|---|---|---|
| R01AA08 | ||
| R01AA05 | ||
| R01AA09 | ||
| R01AA07 | ||
| Sympathomimetics, combinations excl. corticosteroids | ||
|---|---|---|
| R01AB01 | ||
| Antiallergic agents, excl. corticosteroids | ||
|---|---|---|
| R01AC03 | ||
| R01AC01 | ||
| Corticosteroids | ||
|---|---|---|
| R01AD58 | ||
| R01AD01 | ||
| R01AD05 | ||
| R01AD08 | ||
| R01AD12 | ||
| R01AD12 | ||
| R01AD09 | ||
| R01AD59 | ||
| R01AD11 | ||
| Other nasal preparations | ||
|---|---|---|
| R01AX10 | ||
| OTHER NASAL PREPARATIONS | ||
|---|---|---|
| R01AX10 | ||
Reference
- Janssen-Cilag B.V., SmPC Livocab (RVG 13967) 11 sept 2013, www.cbg-meb.nl, Geraadpleegd 30 okt 2014
Changes
Therapeutic Drug Monitoring
Overdose
